EP0910381A1 - Procede de traitement de la douleur - Google Patents
Procede de traitement de la douleurInfo
- Publication number
- EP0910381A1 EP0910381A1 EP97916159A EP97916159A EP0910381A1 EP 0910381 A1 EP0910381 A1 EP 0910381A1 EP 97916159 A EP97916159 A EP 97916159A EP 97916159 A EP97916159 A EP 97916159A EP 0910381 A1 EP0910381 A1 EP 0910381A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pain
- olanzapine
- treatment
- analgesic dosage
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 62
- 230000036407 pain Effects 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 40
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims abstract description 60
- 229960005017 olanzapine Drugs 0.000 claims abstract description 60
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 230000000202 analgesic effect Effects 0.000 claims description 27
- 208000004296 neuralgia Diseases 0.000 claims description 16
- 208000021722 neuropathic pain Diseases 0.000 claims description 13
- 208000005298 acute pain Diseases 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 9
- 206010003246 arthritis Diseases 0.000 claims description 8
- 238000002441 X-ray diffraction Methods 0.000 claims description 6
- 206010019233 Headaches Diseases 0.000 claims description 5
- 231100000869 headache Toxicity 0.000 claims description 5
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 206010050031 Muscle strain Diseases 0.000 claims description 4
- 206010049589 Afterbirth pain Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 206010061363 Skeletal injury Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- -1 4-methyl-l-piperazinyl Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003574 anti-allodynic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- MEUQWHZOUDZXHH-UHFFFAOYSA-N pravadoline Chemical compound C1=CC(OC)=CC=C1C(=O)C(C1=CC=CC=C11)=C(C)N1CCN1CCOCC1 MEUQWHZOUDZXHH-UHFFFAOYSA-N 0.000 description 1
- 229950002577 pravadoline Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 108010010573 serotonin 1C receptor Proteins 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- This invention provides a method for using 2- methyl-4- (4-methyl-l-piperazinyl) -lOH-thieno [2, 3-b] [1, 5] benzodiazepine, (hereinafter referred as "olanzapine”) for the treatment of pain.
- the present invention provides a method which is especially useful for the treatment of acute pain, nociceptive, and neuropathic pain.
- the present invention provides a method for treating pain.
- the present invention provides a method for treating acute self-limiting ailments, low-grade somatic- type acute pain, including for example, but not limited to headache, arthritis, simple muscle strain, and dysmenorrhea.
- the invention further provides a method for treating neuropathic pain. Additionally, this invention provides a method for treating nociceptive pain.
- the ideal analgesic would reduce the awareness of pain, produce analgesia over a wide range of pain types, act satisfactorily whether given orally or parenterally, produce minimal or no side effects, be free from tendency to produce tolerance and drug dependence.
- olanzapine can provide many of the characteristics of an ideal analgesic for the treatment of pain.
- olanzapine can provide antipsychotic activity and is commercially available for the treatment of psychosis.
- Olanzapine is a known compound and described in U.S. Patent No. 5,229,382 as being useful for the treatment of schizophrenia, schizophreniform disorder, acute mania, mild anxiety states, and psychosis.
- U.S. Patent No. 5,229,382 is herein incorporated by reference in- its entirety.
- Applicants have discovered that olanzapine can be useful for the treatment of pain. Olanzapine could address a long felt need for a safe and effective treatment for acute pain.
- the present invention provides a method for treating pain comprising administering an effective amount of olanzapine to an animal in need of such treatment.
- the present invention provides a method for treating acute pain comprising administering to a patient in need thereof, an analgesic dosage of olanzapine or a pharmaceutically acceptable salt thereof.
- the acute pain shall be selected from the group consisting of headache, arthritis, simple muscle strain, and dysmenorrhea.
- the present invention provides a method for treating nociceptive pain comprising administering to a patient in need thereof, an analgesic dosage of olanzapine or a pharmaceutically acceptable salt thereof.
- the present invention provides a method for treating neuropathic pain comprising administering to a patient in need thereof, an analgesic dosage of olanzapine or a pharmaceutically acceptable salt thereof.
- the neuropathic pain is selected from the group consisting of chronic lower back pain, pain associated with arthritis, cancer-associated pain, herpes neuralgia, phantom limb pain, central pain, opioid resistant neuropathic pain, bone injury pain, and pain during labor and delivery.
- the nociceptive pain is selected from the group consisting of post-operative pain, cluster headaches, dental pain, surgical pain, pain resulting from severe, for example third degree, burns. post partum pain, ' angina pain, genitourinary tract related pain, and including cystitis.
- the present invention can provide a method for treating inflammation in an animal comprising administering an anti-inflammatory dose of olanzapine to an animal in need of such treatment.
- Olanzapine is of the formula
- olanzapine will be the Form II olanzapine polymorph having a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:
- a typical example of an x-ray diffraction pattern for Form II is as follows wherein d represents the interplanar spacing and I/Ii represents the typical relative intensities: d I/Ii
- Form II olanzapine polymorph will be administered as the substantially pure Form II olanzapine polymorph.
- substantially pure refers to Form II associated with less than about 5% Form I, preferably less than about 2% Form I, and more preferably less than about 1% Form I. Further, “substantially pure” Form II should contain less than about 0.5% related substances, wherein “related substances” refers to undesired chemical impurities or residual solvent or water. In particular,
- substantially pure Form II should contain less than about 0.05% content of acetonitrile, more preferably, less than about 0.005% .content of acetonitrile. Additionally, the polymorph of the invention should contain less than 0.5% of associated water.
- the polymorph obtainable by the process taught in the '382 patent will be designated as Form I and has a typical x-ray powder diffraction pattern substantially as follows, obtained using a Siemens D5000 x-ray powder diffractometer, wherein d represents the interplanar spacing:
- a typical example of an x-ray diffraction pattern for Form I is as follows wherein d represents the interplanar spacing and I/Ii represents the typical relative intensities:
- the interplanar spacings in the column marked “d” are in Angstroms.
- the typical relative intensities are in the column marked "I/Ii”.
- animal refers to a vertebrate animal. The most preferred animal is a mammal.
- mammal shall refer to the Mammalia class of higher vertebrates.
- the term “mammal” includes, but is not limited to, a human.
- treating includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
- Olanzapine is effective over a wide dosage range; however, it is desirable to administer a dosage that is as low as possible. For example, dosages per day of the olanzapine will normally fall within the range of about 0.1 mg to about 30 mg per day.
- the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the type of acute pain to be treated, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
- the present compounds are preferably administered orally to humans susceptible to or suffering from pain, the compounds may also be administered by a variety of other routes such as the transdermal, parenteral, subcutaneous, intranasal, intramuscular and intravenous routes.
- Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
- treating includes prophylaxis of pain in a patient having a tendency to develop such pain, and the amelioration or elimination of the developed pain once it has been established or alleviation of the characteristic symptoms of such pain.
- This invention envisions that the treatment of pain is most preferably the treatment of pain selected from the group consisting of acute pain, nociceptive pain, and neuropathic pain.
- acute pain shall refer acute self-limiting ailments and low-grade somatic type acute pain.
- the term includes, but is not limited to headache, arthritis, simple muscle strains, and dysmenorrhea.
- nociceptive pain shall refer to pain that is transmitted across intact neuronal pathways.
- neuropathic pain shall refer to pain caused by damage to neural structures, often involving neural supersensitivity. It is preferred that the neuropathic pain is selected from the group consisting of chronic lower back pain, pain associated with arthritis, cancer-associated pain, herpes neuralgia, phantom limb pain, central pain, opioid resistant neuropathic pain, bone injury pain, and pain during labor and delivery.
- the nociceptive pain is selected from the group consisting of post-operative pain, cluster, headaches, dental pain, surgical pain, pain resulting from severe, for example third degree, burns, post partum pain, angina pain, genitourinary tract related pain, and including cystitis.
- the results of pharmacological studies show that olanzapine has muscarinic cholinergic receptor activity. The compound is active at the dopamine D-1 and D-2 receptors as indicated by an IC50 of less than 1 uM in the 3H- SCH233390 (Billard, et al .
- olanzapine is active at the 5-HT-2 receptor and 5-HT1C receptor.
- the complex pharmacological profile of the compound provides a medicament which can be useful for the treatment of pain.
- the dosage administered will, of course, vary depending on known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of the symptoms, kind of concurrent treatment, frequency of treatment, and the effect desired.
- the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 1 mg to about 30 mg olanzapine.
- compositions suitable for internal administration contain from about one half (0.5) milligrams to about 100 milligrams of active ingredient per unit.
- the active ingredient will ordinarily be present in an amount of from about 0.5% to about 95% by weight based on the total weight of the composition.
- compositions include olanzapine or a pharmaceutically acceptable acid addition salt thereof associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
- a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
- the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
- the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
- the active compound can be adsorbed on a granular solid container for example in a sachet.
- suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
- the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents.
- the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
- the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
- auxiliary agents emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
- injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
- Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
- Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
- elixir can be used in cases where a sweetened vehicle can be employed.
- olanzapine is dispensed in unit form comprising from about 0.1 mg to about 30 mg in a pharmaceutically acceptable carrier per unit dosage.
- the solid oral formulation is contained in packaging materials which protect the formulation from moisture and light.
- suitable packaging materials include amber colored high density polyethylene bottles, amber colored glass bottles, and other containers made of a material which inhibits the passage of light.
- the packaging will include a desiccant pack. The container may be sealed with an aluminum foil blister to provide the desired protection and maintain product stability.
- compositions of this invention may be suitable for administration to an animal.
- animals include both domestic animals, for example livestock, laboratory animals, and household pets, and non-domestic animals such as wildlife. More preferredly, the animal is a vertebrate.
- a compound of this invention shall be administered to a mammal. It is especially preferred that the animal is a domestic mammal or a human. The most preferred mammal is a human. For such purposes, a compound of this invention may be administered as a feed additive.
- mice The unexpected analgesic activity of olanzapine is evidenced by tests intially conducted on mice. Mice weighing from about 18-22 grams at the time of testing are used for the following studies. All mice are dosed by the oral route with olanzapine. Doses are coded using a code unknown to the observer. Mouse Writhing Tes " t
- An accepted standard for detecting an comparing the analgesic activity of different classes of analgesic compounds for which there is a good correlation with human analgesic activity is the prevention of acetic acid-induced writhing in mice.
- mice (approximately 4-5 weeks of age) , were obtained from Charles River Laboratories, Portage, MI, and acclimated at least 3 days before testing. Only healthy mice weighing between 22 and 35 g were included in testing. Mice were housed 10/cage in plastic gang cages and given Certified Rodent Chow and water ad libitum. Bedding was changed twice weekly. Room temperature was maintained at 22 +/- 4°C and relative humidity was maintained between 30% and 70%. The photoperiod -was 12 hours of light and 12 hours of dark, with dark onset at approximately 1800 hours.
- suspensions were prepared at target concentrations of 0, 0.3, 0.1, 0.3, and 1 mg olanzapine/ml by the addition of 10% acacia in purified water.
- the vehicle control consisted of 10% acacia in purified water.
- Analgesic activity following administration of olanzapine was evaluated using acetic acid-induced writhing.
- An intraperitoneal injection of acetic acid in mice causes them to exhibit contractions of the abdominal muscles, or writhe (Siegmund et al., 1957) .
- Administration of either opioid or nonopioid analgesics reduces the amount of writing (Collier, 1964) .
- Writhing has been used to define the pharmacology of analgesics such as aspirin and morphine.
- mice were placed in individual clear observation chambers and the total number of writhes ' made by each mouse was counted between 5 and 10 minutes following administration of acetic acid. See, Haubrich, D.R., Ward, S.J., Baiz an, E., Bell, M.R., Bradford, J., Ferrari, R., Miller, M., Perrone, M., Pierson, A.K., Saelens, J.K. and Luttinger, D. :
- mice Another accepted standard for detecting and comparing the analgesic activity of different classes of analgesic compounds for which there is a good correlation with human analgesic activity is the prevention of phenyl-p-benzoquinone induced writhing in mice. [H. Blumberg et al. Proc. Soc. Exp. biol. Med., 118, 763-766 (1965) ] . Mice, treated with various doses of olanzapine or vehicle are injected intraperitoneally with a standard challenge dose of phenyl-p-benzoquinone 5 minutes prior to a designated observation period.
- the pheyl-p- benzoquinone is prepared as about 0.1 mg/ml solution in about 5% by volume of ethanol in water.
- the writhing dose is 1.25 mg/kg injected at a volume of about 0.25ml/10g.
- a "writhe" is indicated by whole body stretching or contracting of the abdomen during an observation period beginning about five minutes after the phenyl-p-benzoquinone dose.
- Tail-flick has been used to define or monitor analgesic levels following exposure to a variety of compounds (D'Amour and Smith, 1941; Harris and Pierson, 1964) .
- the apparatus can be used to test mice, rats or monkeys by focusing a beam of light on the tail and evaluating latency to tail-flick. This test has proven useful for screening weak or strong analgesics (Dewey et. al., 1969).
- Tail flick was used to evaluate the analgesic effects of olanzapine. Approximately 60 minutes following oral administration of olanzapine (0, 0.3, 1, 3, or 10 mg/kg) mice were placed in a holding tube and the time required for each mouse to react (tail flick) to the heat from a beam of light focused on the tail was recorded (Tail Flick Apparatus, Columbus Instruments, Columbus, OH) .
- Olanzapine produced significant analgesic activity with significant increases in tail flick latencies at 1, 3, and 10 mg/kg with respect to control latencies.
- Rats are anesthetized and a nerve ligation procedure performed. The common sciatic nerve is exposed and 4 ligatures tied loosely around it with about 1 mm spacing. One day to 10 weeks after surgery, the nociceptive testing is performed. Rats are orally administered various doses of olanzapine or placebo, prior to testing. Responses to noxious heat are determined by placing the rats in a chamber with a clear glass floor and aiming at the plantar surface of the affected foot a radiant heat source from beneath the floor. Increased latency to withdraw the hind paw is demonstrative- of analgesic activity.
- a double-blind multicenter clinical trial is designed to assess the safety and efficacy of olanzapine. Patients are randomized to olanzapine or placebo.
- the materials for the present invention can be purchased or prepared by a variety of procedures well known to those of ordinary skill in the art.
- Olanzapine can be prepared as described by Chakrabarti in U.S. Patent No 5,229,382 ('382), herein incorporated by reference in its entirety. Further, the following preparations illustrate a method for preparing of the especially preferred Form II olanzapine polymorph.
- Compound characterization methods include, for example, x-ray powder pattern analysis, thermogravimetric analysis (TGA) , differential scanning calorimetery (DSC) , titrametric analysis for water, and H 1 -NMR analysis for solvent content.
- TGA thermogravimetric analysis
- DSC differential scanning calorimetery
- titrametric analysis for water thermogravimetric analysis
- H 1 -NMR analysis for solvent content H 1 -NMR analysis for solvent content.
- a sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction.
- the reaction was heated to 120°C and maintained at that temperature throughout the duration of the reaction.
- the reactions were followed by HPLC until 2 5% of the intermediate 1 was left unreacted.
- the mixture was allowed to cool slowly to 20°C (about 2 hours) .
- the reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath. To this solution with agitation was added 10 volumes reagent grade methanol and the reaction was stirred at 20°C for 30 minutes. Three volumes of water was added slowly over about 30 minutes.
- the reaction slurry was cooled to zero to 5°C and stirred for 30 minutes.
- the product was filtered and the wet cake was washed with chilled methanol.
- the wet cake was dried in vacuo at 45°C overnight.
- the product was identified as technical olanzapine.
- hydroxypropyl cellulose was dissolved in purified water to form a solution for granulation.
- the remaining hydroxypropyl cellulose (total of 4.0% w/w final tablet weight), which was an extra fine grade, was combined with the olanzapine (1.18% w/w), lactose (79.32% w/w) and a portion of the crospovidone (5% w/w) in a high shear granulator. All ingredients were security sieved prior to addition and dry blended in the granulator. This mixture was then granulated with the hydroxypropyl cellulose solution in the high shear granulator. The granulation was wet sized using standard methods. The wet granulation was then dried in a fluidized bed dryer and sized. The material was then added to a tumble bin mixer.
- the running powders consisting of microcrystalline cellulose (granular) (10% w/w), magnesium stearate (0.5% w/w), and the remainder of the crospovidone were added to the sized granulation. The mixture was blended and compressed with the appropriate tooling on tablet compression equipment.
- Hydroxypropyl methylcellulose (10% w/w) was mixed with purified water to form a solution. Core tablets were divided into approximately equal sections and spray coated with the hydroxypropyl methylcellulose solution . The operation was performed in a perforated coating pan.
- Color Mixture White (hydroxypropyl methylcellulose, polyethylene glycol, polysorbate 80, and titanium dioxide) was mixed with purified water to form the coating suspension. Subcoated tablets were divided into approximately equal sections and spray coated with the coating suspension described above. The operation was performed in a perforated coating pan.
- the coated tablets were lightly dusted with carnauba wax and imprinted with appropriate identification.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1413196P | 1996-03-25 | 1996-03-25 | |
US1415396P | 1996-03-25 | 1996-03-25 | |
US1413396P | 1996-03-25 | 1996-03-25 | |
US14153P | 1996-03-25 | ||
US14133P | 1996-03-25 | ||
US14131P | 1996-03-25 | ||
PCT/US1997/004626 WO1997035583A1 (fr) | 1996-03-25 | 1997-03-24 | Procede de traitement de la douleur |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0910381A1 true EP0910381A1 (fr) | 1999-04-28 |
EP0910381A4 EP0910381A4 (fr) | 2002-10-09 |
Family
ID=27360028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97916159A Withdrawn EP0910381A4 (fr) | 1996-03-25 | 1997-03-24 | Procede de traitement de la douleur |
Country Status (14)
Country | Link |
---|---|
US (1) | US6258807B1 (fr) |
EP (1) | EP0910381A4 (fr) |
JP (1) | JP2001517202A (fr) |
CN (1) | CN1219878A (fr) |
AU (1) | AU721338B2 (fr) |
BR (1) | BR9708246A (fr) |
CA (1) | CA2248873A1 (fr) |
CZ (1) | CZ298198A3 (fr) |
EA (1) | EA199800866A1 (fr) |
IL (1) | IL126064A0 (fr) |
NO (1) | NO984446L (fr) |
PL (1) | PL329217A1 (fr) |
WO (1) | WO1997035583A1 (fr) |
YU (1) | YU42298A (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014021803A1 (fr) | 2012-07-31 | 2014-02-06 | Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. | Utilisation d'olanzapine chez des animaux |
WO2014021804A1 (fr) | 2012-07-31 | 2014-02-06 | Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. | Procédé visant à augmenter la production de viande et de lait |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0904083A4 (fr) * | 1996-03-25 | 2002-05-22 | Lilly Co Eli | Methode d'anesthesie |
AU725556B2 (en) * | 1996-03-25 | 2000-10-12 | Eli Lilly And Company | Method for treating pain |
AU2003295823B2 (en) * | 2002-11-26 | 2009-11-05 | Alexza Pharmaceuticals, Inc. | Treatment of headache with antipsychotics delivered by inhalation |
DK1567164T3 (da) | 2002-11-26 | 2009-05-18 | Alexza Pharmaceuticals Inc | Anvendelse af loxapin til fremstilling af et lægemiddel til behandling af smerte |
US7795266B2 (en) * | 2003-09-25 | 2010-09-14 | Helton David R | Tetrahydroindolone derivatives for treament of neurological conditions |
US20050107439A1 (en) * | 2003-11-10 | 2005-05-19 | Helton David R. | Composition and method for treating emesis |
US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US20080026054A1 (en) * | 2007-04-27 | 2008-01-31 | Nectid Inc. | Novel anelgesic combination |
WO2009062134A1 (fr) * | 2007-11-09 | 2009-05-14 | Cenomed Biosciences, Llc | Traitement des troubles du stress post-traumatique avec des composés de tétrahydroindolone et d'arylpipérazine |
US20090264443A1 (en) * | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
CN106243096B (zh) * | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | 三环类药物的新用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5246935A (en) * | 1990-08-24 | 1993-09-21 | Novo Nordisk A/S | Piperazinyl derivatives and methods of treating central nervous system ailments relating to the 5-ht2 receptor system |
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
EP0733635A1 (fr) * | 1995-03-24 | 1996-09-25 | Eli Lilly And Company | Formes de cristaux d'in dérivé de thieno(2,3-B)(1,5)benzodiazepine et procédé pour leur préparation |
WO1997035582A1 (fr) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Technique de traitement de la douleur due a la migraine |
WO1997035586A1 (fr) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Methode de traitement de la douleur |
WO1997035585A1 (fr) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Methode d'anesthesie |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994924A (en) * | 1975-11-04 | 1976-11-30 | American Cyanamid Company | 4,5,6,7-Tetra hydro-7-oxobenzo(B)thien-4-yl isocyanate and isothiocyanate |
PT582368E (pt) * | 1992-05-29 | 2001-05-31 | Lilly Co Eli | Derivados de tienobenzodiazepina para o tratamento de doencas de cns |
US5605911A (en) * | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
-
1997
- 1997-03-24 AU AU23408/97A patent/AU721338B2/en not_active Ceased
- 1997-03-24 US US08/823,460 patent/US6258807B1/en not_active Expired - Fee Related
- 1997-03-24 BR BR9708246A patent/BR9708246A/pt not_active Application Discontinuation
- 1997-03-24 IL IL12606497A patent/IL126064A0/xx unknown
- 1997-03-24 PL PL97329217A patent/PL329217A1/xx unknown
- 1997-03-24 CZ CZ982981A patent/CZ298198A3/cs unknown
- 1997-03-24 CA CA002248873A patent/CA2248873A1/fr not_active Abandoned
- 1997-03-24 CN CN97194952A patent/CN1219878A/zh active Pending
- 1997-03-24 WO PCT/US1997/004626 patent/WO1997035583A1/fr not_active Application Discontinuation
- 1997-03-24 JP JP53450997A patent/JP2001517202A/ja not_active Ceased
- 1997-03-24 EP EP97916159A patent/EP0910381A4/fr not_active Withdrawn
-
1998
- 1998-09-24 NO NO984446A patent/NO984446L/no not_active Application Discontinuation
- 1998-09-25 YU YU42298A patent/YU42298A/sh unknown
- 1998-10-23 EA EA199800866A patent/EA199800866A1/ru unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
US5246935A (en) * | 1990-08-24 | 1993-09-21 | Novo Nordisk A/S | Piperazinyl derivatives and methods of treating central nervous system ailments relating to the 5-ht2 receptor system |
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
EP0733635A1 (fr) * | 1995-03-24 | 1996-09-25 | Eli Lilly And Company | Formes de cristaux d'in dérivé de thieno(2,3-B)(1,5)benzodiazepine et procédé pour leur préparation |
WO1997035582A1 (fr) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Technique de traitement de la douleur due a la migraine |
WO1997035586A1 (fr) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Methode de traitement de la douleur |
WO1997035585A1 (fr) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Methode d'anesthesie |
Non-Patent Citations (2)
Title |
---|
BALDWIN D S ET AL: "FIRST CLINICAL EXPERIENCE WITH OLANZAPINE (LY 170053): RESULTS OF AN OPEN-LABEL SAFETY AND DOSE-RANGING STUDY IN PATIENTS WITH SCHIZOPHRENIA" INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, CLINICAL NEUROSCIENCE PUBLISHERS, LONDON, GB, vol. 10, no. 4, 1995, pages 239-244, XP002051729 ISSN: 0268-1315 * |
See also references of WO9735583A1 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014021803A1 (fr) | 2012-07-31 | 2014-02-06 | Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. | Utilisation d'olanzapine chez des animaux |
WO2014021804A1 (fr) | 2012-07-31 | 2014-02-06 | Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. | Procédé visant à augmenter la production de viande et de lait |
Also Published As
Publication number | Publication date |
---|---|
EA199800866A1 (ru) | 1999-06-24 |
BR9708246A (pt) | 1999-07-27 |
YU42298A (sh) | 1999-09-27 |
NO984446L (no) | 1998-11-25 |
EP0910381A4 (fr) | 2002-10-09 |
PL329217A1 (en) | 1999-03-15 |
CN1219878A (zh) | 1999-06-16 |
IL126064A0 (en) | 1999-05-09 |
AU721338B2 (en) | 2000-06-29 |
NO984446D0 (no) | 1998-09-24 |
AU2340897A (en) | 1997-10-17 |
US6258807B1 (en) | 2001-07-10 |
WO1997035583A1 (fr) | 1997-10-02 |
JP2001517202A (ja) | 2001-10-02 |
CZ298198A3 (cs) | 1999-06-16 |
CA2248873A1 (fr) | 1997-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5945416A (en) | Method for treating pain | |
US6258807B1 (en) | Method for treating pain | |
AU721290B2 (en) | Method for treating migraine pain | |
AU709181B2 (en) | Method for treating autism | |
AU734011B2 (en) | Method for treating bipolar disorder | |
AU719517B2 (en) | Method for treating excessive aggression | |
WO1997033586A1 (fr) | Methode de traitement de la pharmacodependance | |
AU724245B2 (en) | Method for treating insomnia | |
MXPA98007808A (en) | Use of olanzapine to treat the do | |
AU725940C (en) | Method for treating substance abuse | |
KR20000004964A (ko) | 통증 치료 방법 | |
CA2248905A1 (fr) | Methode de traitement des troubles bipolaires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980915 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 19980915;LT PAYMENT 19980915;LV PAYMENT 19980915;RO PAYMENT 19980915;SI PAYMENT 19980915 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020820 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI MC NL PT SE |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030326 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040629 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1020526 Country of ref document: HK |